Clinical Trial Update: Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of docetaxel and gemcitabine in metastatic esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Samsung Medical Center | Conditions: Metastatic Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED